Hsbc Holdings PLC purchased a new stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,983 shares of the medical instruments supplier’s stock, valued at approximately $414,000.
Several other hedge funds have also made changes to their positions in the company. Kilter Group LLC acquired a new stake in Merit Medical Systems during the 2nd quarter valued at $25,000. Los Angeles Capital Management LLC acquired a new stake in shares of Merit Medical Systems in the fourth quarter worth $25,000. Covestor Ltd boosted its position in shares of Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 336 shares during the period. Danske Bank A S purchased a new position in shares of Merit Medical Systems during the third quarter valued at $42,000. Finally, Quarry LP grew its holdings in shares of Merit Medical Systems by 185.9% during the third quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock valued at $44,000 after buying an additional 342 shares in the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.
Merit Medical Systems Stock Performance MMSI opened at $88.57 on Friday. The company has a market cap of $5.29 billion, a PE ratio of 36.60, a price-to-earnings-growth ratio of 2.25 and a beta of 0.49. The stock has a 50-day moving average of $81.49 and a 200-day moving average of $73.11. Merit Medical Systems, Inc. has a 52-week low of $59.74 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The business had revenue of $418.84 million for the quarter, compared to the consensus estimate of $405.25 million. During the same period last year, the business earned $1.01 EPS. The firm’s revenue was up 9.5% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, equities research analysts forecast that Merit Medical Systems, Inc. will post 3.84 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Several equities research analysts recently issued reports on the company. Canaccord Genuity Group increased their price objective on Merit Medical Systems from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Weiss Ratings raised Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. JPMorgan Chase & Co. upped their target price on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Robert W. Baird set a $98.00 price target on shares of Merit Medical Systems in a research report on Friday, July 31st. Finally, Piper Sandler raised their price target on shares of Merit Medical Systems from $96.00 to $106.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus target price of $100.00.
Read Our Latest Analysis on MMSI
(Free Report)
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Further Reading Five stocks we like better than Merit Medical Systems The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
Jupiter Topco LLC bought a new position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 27,531 shares of the medical instruments supplier’s stock, valued at approximately $1,908,000.
Several other hedge funds have also recently bought and sold shares of the business. J. Goldman & Co LP acquired a new stake in shares of Merit Medical Systems in the second quarter worth about $16,835,000. Hsbc Holdings PLC acquired a new position in shares of Merit Medical Systems during the 2nd quarter valued at about $414,000. Canada Pension Plan Investment Board bought a new position in shares of Merit Medical Systems in the 2nd quarter valued at approximately $388,000. Legal & General Group Plc bought a new position in shares of Merit Medical Systems in the 2nd quarter valued at approximately $9,472,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Merit Medical Systems in the 2nd quarter worth approximately $33,591,000. 99.66% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades A number of equities research analysts have issued reports on MMSI shares. Barrington Research set a $114.00 target price on Merit Medical Systems in a research report on Friday, July 31st. BTIG Research reissued a “buy” rating and issued a $105.00 price target on shares of Merit Medical Systems in a research report on Tuesday, August 11th. Wells Fargo & Company boosted their price objective on shares of Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Weiss Ratings raised shares of Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Finally, Robert W. Baird set a $98.00 target price on shares of Merit Medical Systems in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.00.
Check Out Our Latest Analysis on MMSI Merit Medical Systems Price Performance NASDAQ MMSI opened at $88.57 on Friday. The stock has a 50-day simple moving average of $81.49 and a 200 day simple moving average of $73.11. Merit Medical Systems, Inc. has a twelve month low of $59.74 and a twelve month high of $94.75. The stock has a market capitalization of $5.29 billion, a PE ratio of 36.60, a P/E/G ratio of 2.25 and a beta of 0.49. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The firm had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. During the same quarter last year, the firm posted $1.01 EPS. The company’s revenue was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Research analysts anticipate that Merit Medical Systems, Inc. will post 3.84 EPS for the current year.
(Free Report)
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Featured Articles Five stocks we like better than Merit Medical Systems The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern Want to see what other hedge funds are holding MMSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report).
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences:
The Wells Fargo 2026 Healthcare Conference, which is being held in Boston, MA from September 8-10, 2026.
Management is scheduled to participate in a fireside chat on Thursday, September 10th at 8:45 a.m. Eastern Time. The Baird 2026 Global Healthcare Conference, which is being held in New York, NY on September 15, 2026.
Management is scheduled to present on Tuesday, September 15th at 8:30 a.m. Eastern Time. The 19th Annual Barrington Research Virtual Fall Investment Conference, which is being held virtually on September 22, 2026.
Management is scheduled to participate in 1x1 meetings only, with no formal presentation session. The Sidoti Small Cap Conference, which is being held virtually from September 23-24, 2026.
Management is scheduled to participate in 1x1 meetings only on Wednesday, September 23rd, with no formal presentation session. Live audio webcasts of the fireside chats will be accessible under the “Events” section of Merit’s investor relations website at Investor Events and Presentations - Merit Medical. Replays of the fireside chats will be available on this same website for approximately 90 days.
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide.
Key Takeaways Merit Medical's broad portfolio and R&D investments support growth across key medical-device markets.WRAPSODY's WAVE trial showed 48.6% patency versus 29.8% for angioplasty at 24 months.Tariffs are expected to reduce 2026 results by $16 million, or 21 cents per share, amid trade uncertainty. Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expected to contribute further. However, tariffs and trade policy headwinds and China macro pressure persist.
This Zacks Rank #2 (Buy) company’s shares have gained 2.9% in the year-to-date period compared with the industry’s 6.5% growth and the S&P 500’s 10.8% rise.
The renowned medical device provider has a market capitalization of $5.41 billion. The company projects 10.4% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 14.1% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
MMSI’s Growth DriversBroad Product Portfolio and Continued R&D Investment: Merit Medical benefits from a diversified portfolio across cardiology, radiology, oncology, critical care and endoscopy. Recent launches and acquisitions, including the Resilience Through-the-Scope Esophageal Stent, View Point Medical’s OneMark, SCOUT MD and the integration of Biolife’s StatSeal, are expanding its presence across diagnosis, localization, therapy and procedural support. R&D spending remained focused on product renewal, with expenses representing 6.1% of sales in the second quarter of 2026, up 4.2% year over year. The company is also prioritizing its pipeline and potential tuck-in acquisitions under its 2027-2029 strategic plan.
WRAPSODY Provides a Multi-Year Renal Therapy Opportunity: Merit Medical’s WRAPSODY Cell-Impermeable Endoprosthesis remains a growth opportunity as the company rebuilds U.S. account activity and expands physician adoption following its recall. The device demonstrated favorable 24-month clinical outcomes in the WAVE trial, with target lesion primary patency of 48.6% versus 29.8% for angioplasty in the randomized arteriovenous fistula arm. Positive physician feedback and use across hospital and non-hospital settings support continued adoption, with MMSI maintaining a measured $7 million U.S. revenue assumption.
Global Exposure and Focused Growth Strategy: Merit Medical’s geographic diversification provides multiple avenues for expansion. In the second quarter of 2026, domestic revenues increased 11.5% on a constant-currency basis, while international revenues rose 4.7%. The company is expanding Biolife internationally and developing a 2027-2029 strategic plan focused on growth opportunities, organizational capabilities and capital allocation. Its planned M&A framework will emphasize targeted tuck-in acquisitions and high-growth procedures where it can leverage both foundational and therapeutic products.
Key Challenges for MMSI StockTariff Concerns: Merit Medical remains exposed to trade policy changes, geopolitical instability and global macroeconomic uncertainty. The company received $6.9 million in tariff refunds during the second quarter but still incurred approximately $2 million in incremental tariff costs. Management now expects tariffs to have a $16 million, or 21 cents per share, impact on 2026 results, up from its previous $15 million estimate. The outlook also excludes trade actions implemented after July 30, 2026, highlighting ongoing forecasting uncertainty. Further tariff changes, refunds and related sourcing, manufacturing or pricing actions could create additional pressure on operating performance.
Stiff Competition in MedTech Space: Merit Medical competes with diversified medical-device companies and specialized participants across several product categories. The company’s expanding therapeutic portfolio increases the need to support multiple launches while defending established product positions. Management acknowledged that competitors in the WRAPSODY market are not standing still and described the commercial environment as a competitive battle.
Merit Medical is also introducing SCOUT MD and OneMark into a market where physician preferences and price differences influence technology selection. Management is reviewing product families under its 2027-2029 strategic planning process to determine whether they remain appropriate for the longer-term portfolio. The need to prioritize resources across a broad product base can add execution complexity. Competitive substitution or pricing actions could slow adoption of newer technologies and require additional commercial investment.
Estimate TrendMMSI is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved 0.9% north to $4.30.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $410.4 million, suggesting a 6.8% rise from the year-ago reported number. The consensus mark for EPS is pegged at $1.04, implying 13% growth from the prior-year reported figure.
Other Stocks to ConsiderSome other top-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical’s shares have lost 7.8% compared with the industry’s 8.9% decline in the year-to-date period.
Veracyte, currently flaunting a Zacks Rank #1, has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Veracyte’s shares have risen 3.2% against the industry’s 8.9% decline in the year-to-date period.
West Pharmaceutical, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
West Pharmaceutical’s shares have gained 23% compared with the industry’s 6.5% growth in the year-to-date period.
American Capital Management Inc. acquired a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 104,967 shares of the medical instruments supplier’s stock, valued at approximately $7,278,000. American Capital Management Inc. owned about 0.18% of Merit Medical Systems at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of MMSI. AQR Capital Management LLC boosted its holdings in Merit Medical Systems by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock worth $1,730,000 after buying an additional 1,114 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Merit Medical Systems by 16.9% during the first quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock worth $76,039,000 after acquiring an additional 103,878 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Merit Medical Systems by 745.9% in the second quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock worth $86,000 after acquiring an additional 813 shares during the period. First Trust Advisors LP boosted its holdings in shares of Merit Medical Systems by 24.8% in the second quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock worth $5,535,000 after acquiring an additional 11,770 shares during the period. Finally, Cerity Partners LLC grew its position in shares of Merit Medical Systems by 9.1% in the second quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after purchasing an additional 251 shares in the last quarter. 99.66% of the stock is owned by institutional investors.
Analysts Set New Price Targets Several analysts have issued reports on MMSI shares. Piper Sandler increased their target price on shares of Merit Medical Systems from $96.00 to $106.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. boosted their price target on shares of Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and issued a $105.00 price target on shares of Merit Medical Systems in a report on Tuesday, August 11th. Wells Fargo & Company increased their price objective on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, Weiss Ratings raised Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.00.
Check Out Our Latest Research Report on MMSI Merit Medical Systems Price Performance Shares of NASDAQ MMSI opened at $90.54 on Thursday. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $94.75. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.20 and a quick ratio of 2.79. The company’s 50-day moving average is $78.85 and its 200 day moving average is $72.74. The stock has a market capitalization of $5.41 billion, a P/E ratio of 37.41, a P/E/G ratio of 2.27 and a beta of 0.49.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.23. The company had revenue of $418.84 million during the quarter, compared to analyst estimates of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. Merit Medical Systems’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business earned $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, sell-side analysts expect that Merit Medical Systems, Inc. will post 3.84 earnings per share for the current year.
Key Headlines Impacting Merit Medical Systems Here are the key news stories impacting Merit Medical Systems this week:
Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth. Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion. Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering. Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact. Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short. (Free Report)
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Featured Stories Five stocks we like better than Merit Medical Systems Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks? Want to see what other hedge funds are holding MMSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report).
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
Freestone Grove Partners LP purchased a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,554 shares of the medical instruments supplier’s stock, valued at approximately $1,148,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp lifted its stake in shares of Merit Medical Systems by 1.5% during the 4th quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock valued at $196,645,000 after buying an additional 32,459 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Merit Medical Systems by 3.9% in the 1st quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock worth $149,407,000 after buying an additional 81,030 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock worth $183,137,000 after buying an additional 234,682 shares in the last quarter. Wellington Management Group LLP raised its holdings in Merit Medical Systems by 7.0% during the fourth quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock valued at $116,963,000 after acquiring an additional 86,504 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Merit Medical Systems by 1.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock valued at $85,287,000 after acquiring an additional 12,285 shares during the period. 99.66% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes MMSI has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Canaccord Genuity Group lifted their target price on Merit Medical Systems from $85.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Raymond James Financial reissued an “outperform” rating and issued a $100.00 price target on shares of Merit Medical Systems in a report on Friday, July 31st. Weiss Ratings raised shares of Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.00.
Get Our Latest Stock Report on MMSI Merit Medical Systems Trading Up 1.1% Shares of Merit Medical Systems stock opened at $90.49 on Friday. Merit Medical Systems, Inc. has a twelve month low of $59.74 and a twelve month high of $94.75. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $79.77 and a 200-day moving average price of $72.91. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of 37.39, a PEG ratio of 2.26 and a beta of 0.49.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The company had revenue of $418.84 million for the quarter, compared to the consensus estimate of $405.25 million. During the same period in the previous year, the business earned $1.01 earnings per share. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Equities research analysts anticipate that Merit Medical Systems, Inc. will post 3.84 EPS for the current fiscal year.
Merit Medical Systems Company Profile (Free Report)
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Featured Stories Five stocks we like better than Merit Medical Systems From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
Key Takeaways Merit Medical raised its 2026 revenue and adjusted earnings outlook after stronger first-half results.Therapeutic products are projected to grow 9.1% from 2025-2028, versus 4.7% for Foundational products.Merit Medical trades at 20.3X forward earnings versus 17.6X for its sub-industry, raising execution pressure. Merit Medical Systems, Inc. (MMSI - Free Report) is showing a better operating trajectory as therapeutic products, recent launches and acquisitions broaden its growth mix. Earnings expectations have also improved, strengthening the fundamental case.
The trade-off is valuation. MMSI still carries a premium to its Zacks sub-industry, leaving less room for execution misses even as its growth outlook becomes more favorable.
Merit Medical’s Growth Case Is Getting StrongerFor 2026, the Zacks model projects revenues and adjusted earnings per share to increase 7.6% and 11.5%, respectively. The company also raised its 2026 revenue and adjusted earnings outlook after stronger-than-expected first-half results.
From 2025 through 2028, revenues and adjusted earnings are projected to post compound annual growth rates of 6.2% and 8.9%, respectively. Therapeutic products are expected to grow at a 9.1% rate, ahead of 4.7% for Foundational products, improving the mix toward faster-growing categories.
Image Source: Zacks Investment Research
MMSI’s Valuation Leaves Less Room for ErrorMMSI trades at 20.3X forward 12-month earnings compared with 17.6X for its Zacks sub-industry. That premium means further upside depends more heavily on sustained revenue growth, margin execution and continued earnings delivery.
The multiple is below MMSI's five-year median of 24.5X, which tempers the valuation concern. Still, the stock is not inexpensive relative to its sub-industry, so stronger fundamentals need to translate into consistent results.
Image Source: Zacks Investment Research
New MMSI Platforms Add Longer-Term OptionalityThe View Point Medical acquisition added the OneMark Detection Imaging System and OneMark Tissue Markers to Merit Medical's oncology portfolio. Combined with the late-May launch of SCOUT MD, the technologies broaden breast-care localization options across diagnosis and surgery.
Endoscopy also gained the Resilience Through-the-Scope Esophageal Stent and C2 CryoBalloon. WRAPSODY remains a multi-year renal-therapy opportunity, although the unchanged $7 million U.S. revenue assumption for 2026 keeps near-term expectations measured.
Image Source: Zacks Investment Research
Merit Medical Faces Tariff and Execution RisksManagement now expects a 2026 tariff burden of approximately $16 million, or 21 cents per share, up from its prior assumption. Buyer consolidation, distributor dependence in some international markets and currency volatility can also pressure pricing and visibility.
Competition remains broad. Boston Scientific Corporation (BSX - Free Report) operates across endoscopy and cardiovascular devices, creating overlap with several Merit Medical procedure areas. Medtronic plc (MDT - Free Report) also reports Cardiovascular and Surgical & Endoscopy businesses, underscoring the need for Merit Medical to support launches while defending established positions.
MMSI’s Balance Sheet Supports Strategic FlexibilityMerit Medical ended the second quarter with $448.7 million in cash and cash equivalents and $736.3 million in long-term debt. Its debt-to-capital ratio was 30.5%, below the industry level of 50.5%.
Management is building an M&A playbook and broader capital-allocation framework as part of its 2027-2029 strategic planning process. That liquidity can support potential tuck-in acquisitions and product-pipeline priorities, although deployment discipline remains important.
MMSI Signals Support a Patient StanceMMSI's improving growth mix, portfolio expansion and stronger earnings outlook support the fundamental case, but the valuation premium and execution risks argue against treating the setup as an easy decision. The balance remains constructive rather than decisive.
The stock currently carries a Zacks Rank #3 (Hold). Its Momentum Score of A and VGM Score of B are favorable, while its Value Score of C and Growth Score of C are more middle-of-the-pack. Taken together, the signals support patience while investors watch whether execution can justify the premium. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Key Takeaways Merit Medical shares rose 22.2% in a month as Q2 revenue and adjusted earnings topped estimates.Therapeutic revenue rose 15%, led by 24% growth in Cardiac Therapies and 29% in Endoscopy.Merit Medical raised 2026 EPS and revenue guidance, while tariff costs are expected near $16 million. Merit Medical Systems, Inc. (MMSI - Free Report) shares have climbed 22.2% in the past month, shifting attention from the size of the rally to whether earnings momentum can support it.
The latest quarter provided stronger evidence. Revenue growth accelerated, adjusted earnings beat expectations and management raised its 2026 outlook. Still, the stock now trades above its sub-industry valuation multiple, while tariffs and competitive pressure remain meaningful offsets.
Q2 Strength Gives MMSI’s Rally Fundamental SupportSecond-quarter 2026 revenues rose 9.5% year over year to $418.8 million and surpassed the Zacks Consensus Estimate by 3.5%. Adjusted earnings of $1.19 per share increased 18% and beat the consensus mark by 23.9%.
Organic revenues increased 9% at constant currency, excluding acquisition contributions and the DualCap divestiture. U.S. revenues increased 11.5% at constant currency, while international revenues rose 4.7%, giving the quarter a broader operating base for the recent share-price advance.
Merit Medical’s Therapeutic Mix Is AcceleratingTherapeutic revenues increased 15% on a reported basis, while organic sales advanced 11.7%. Cardiac Therapies and Endoscopy revenues rose 24% and 29%, respectively, making the faster-growing therapeutic portfolio an increasingly important part of the mix.
Merit Medical has also broadened its oncology and endoscopy exposure through OneMark and the C2 CryoBalloon. Competition remains substantial. Boston Scientific Corporation (BSX - Free Report) competes across cardiovascular, endoscopy and interventional oncology categories. Medtronic plc (MDT - Free Report) also has broad cardiovascular and endoscopy exposure, raising the importance of product differentiation and commercial execution.
MMSI Margin Gains Need a Tariff Reality CheckAdjusted gross margin expanded 260 basis points to 55.8%, supported by pricing, product mix, acquisition performance, manufacturing transfers, automation and lower reliance on air freight. Adjusted operating margin also rose 140 basis points to 22.6%.
The tariff-adjusted picture is less dramatic. Excluding tariff refunds, adjusted gross margin was 54.2%, up 98 basis points, while adjusted operating margin was 20.9%, down 22 basis points. Management now expects approximately $16 million of tariff costs in 2026, which could limit further margin progress.
MMSI Valuation Tests How Much Upside Is Priced InMMSI trades at 20.3X forward 12-month earnings versus 17.6X for its Zacks sub-industry. That premium suggests investors are already assigning value to the improving growth and earnings outlook.
The multiple is still below the stock’s five-year median of 24.5X. That leaves room for a higher valuation if execution stays strong, but the current premium reduces the margin for disappointment after the recent rally.
Image Source: Zacks Investment Research
Merit Medical’s Estimates Still Point HigherThe Zacks Consensus Estimate for 2026 earnings has moved 5.3% higher in the past four weeks. Management also raised adjusted earnings guidance to $4.25-$4.35 per share from $4.01-$4.15 and lifted its 2026 revenue range to $1.631-$1.643 billion.
Estimate momentum is constructive, though risks remain. Consolidation among healthcare buyers can pressure pricing, while management’s 2026 outlook assumes an approximately 80-basis-point benefit to reported revenue growth from foreign exchange. Currency moves can therefore add variability to reported results.
Image Source: Zacks Investment Research
MMSI Momentum Leads Its Style ProfileThe 22.2% monthly gain now has better fundamental support from organic growth, margin progress and estimate revisions. Valuation and tariff exposure, however, make the next leg of the move more dependent on continued execution.
MMSI currently carries a Zacks Rank #3 (Hold), pointing to a balanced short-term view. Its Momentum Score of A is favorable, while its Value Score of C and Growth Score of C keep the style picture mixed. The VGM Score of B adds support, but the Hold rank stops short of signaling the stronger near-term setup associated with top-ranked stocks. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. MMSI has a Momentum Style Score of A, and shares are up 25.8% over the past four weeks.
For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.19 to $4.26 per share. MMSI boasts an average earnings surprise of +14.1%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MMSI should be on investors' short list.
SOUTH JORDAN, Utah, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer of healthcare technology, today announced that Sheri Lewis has agreed to join Merit as Executive Vice President of Global Operations, effective August 31, 2026.
Ms. Lewis brings three decades of experience across global operations, manufacturing, and supply chain management. She previously held senior roles at SkinHealth Systems, Inc., Avantor, Medtronic, and Honeywell, leading global manufacturing, distribution, logistics, supply chain, quality, regulatory, environmental health and safety, and operational excellence functions across large, complex organizations.
"Sheri is an accomplished operations executive with a strong record of leading complex organizations and building high-performing teams," said Martha G. Aronson, Merit’s President and Chief Executive Officer. "Her experience strengthening integrated business processes, ensuring product availability, and driving global operational excellence will be important as Merit continues to scale globally and execute its long-term growth strategy."
To support continuity, Mr. Peterson will move into the role of Senior Advisor, where he will help ensure a smooth transition through March 5, 2027. At that time, Mr. Peterson will complete his service to Merit after more than 32 years with the company.
Mr. Peterson has held leadership roles across Merit’s operations and engineering functions, most recently serving as Chief Operating Officer for the past four years. Throughout his career, he has strengthened product quality, improved on-time delivery, advanced operational efficiencies, and driven cost reductions. He also helped navigate supply chain constraints, raw material shortages, and the operational challenges of the COVID-19 pandemic. Mr. Peterson has consistently shown a deep commitment to supporting employees and their well-being.
"Neil has been a dedicated and respected leader at Merit. His operational discipline, commitment to execution, and deep knowledge of our manufacturing and supply chain network have contributed meaningfully to the company’s growth and performance," added Aronson. "We are grateful for his many contributions and for the important role he has played in strengthening our global operations."
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide.
Merit Medical Systems (NASDAQ:MMSI) is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event.
Parra said the company remains “hyper-focused” on executing its current CGI plan and does not want to “drop the football on the one-yard line.” He said the company is working with CEO Martha on the next three-year plan after she spent time visiting company sites and participating in the strategic-planning process.
While Parra did not provide new targets, he said Merit is evaluating whether the core metrics used in its past long-range plans remain the right measures for the next plan. Those prior targets included organic revenue growth, operating-margin expansion and cumulative free cash flow. The company has previously presented new plans either in November before a program begins or alongside its fourth-quarter results, though Parra said management is also considering whether to provide the update sooner.
Portfolio Review Could Lead to Targeted Changes
Merit is reviewing its portfolio platform by platform to determine where it is performing well, where it needs improvement and which assets may not fit the company’s strategic call points, Parra said. He described the process as “strategic and surgical,” rather than one involving large divestitures.
The company has assembled businesses across oncology, endoscopy, renal therapies and access through acquisitions, Parra said. While he characterized the portfolio as being in attractive markets and procedures, he said there could be opportunities to prune smaller assets that sit outside Merit’s primary call points.
Parra cited the company’s divestiture of DualCap as an example of the type of smaller, targeted action management could consider. He said it was too early to determine whether further changes would extend beyond SKU rationalization or involve additional product-line sales.
Margin Efforts Remain Broad-Based
Parra said Merit has delivered 850 basis points of operating-margin improvement and could approach 950 basis points if it reaches the high end of its current-year guidance. He said the company expects further gains to come from continuing to address a broad range of factors, including pricing, sales mix, new product introductions, acquisitions, manufacturing efficiency, automation, lower-cost production transfers, raw materials, scale and logistics.
Rather than relying on a single initiative, Parra said Merit aims to prevent gains in one area from being offset by weaker execution elsewhere. He described the company as being “perpetually” in the seventh inning of margin work: past the heaviest lifting but still able to apply lessons from its prior transformation efforts consistently.
On capital allocation, Parra said Merit remains interested in tuck-in acquisitions across its existing platforms, depending on available opportunities. Share repurchases have also been part of management’s strategic-planning discussions, he said, particularly after medtech stocks experienced pressure earlier in the year.
Management Points to Guidance for Underlying Growth
Merit reported 9% organic growth in the second quarter, its strongest organic-growth result in three years, along with a 22.6% non-GAAP operating margin. Parra said the quarter benefited from an OEM rebound and resolution of a renal recall, but said the result did not surprise management given the underlying performance seen in the first quarter.
The company raised its organic-growth outlook to 6.9% to 7.5% and its adjusted earnings-per-share outlook to $4.25 to $4.35. Parra directed investors to the full-year guidance as the best measure of the company’s expected run rate, while adding that Merit has not seen unusual demand weakness or softness in procedure volumes beyond normal seasonal patterns.
Parra said hospitals could face pressure from broader reimbursement and funding issues, but Merit’s products generally carry a relatively low average selling price and include products such as access, delivery and closure devices that are required in procedures. He said the company’s broad portfolio, vertical integration and product quality help support its value proposition to health systems.
OneMark, Endoscopy and OEM Highlight Growth Areas
Executive Vice President of Corporate Finance and Treasury Travis McDougal said the OneMark acquisition expands Merit’s participation earlier in the patient pathway, including lower-risk biopsies, and increases the company’s addressable market to roughly $1.3 billion. He said OneMark and the SCOUT MD platform can serve as part of a continuum of care, although management has incorporated some potential cannibalization into its guidance.
Parra said the company’s sales force is enthusiastic about having a lower-cost option for cases in which the SCOUT system may not be economically appropriate. He added that the OneMark integration is progressing well.
Merit’s endoscopy business grew 29% year over year. Parra said the company does not promise that growth rate will persist, but management is encouraged by the combination of acquired products and new product introductions. McDougal said the segment’s offerings span a patient pathway that includes GERD treatment, Barrett’s esophagus and Merit’s legacy endoscopy products.
Parra also said second-quarter OEM performance was broad-based, supported by a new customer agreement and product deliveries. Management expects additional deliveries to that customer in the second half and said it remains confident in mid- to high-single-digit growth for the OEM business.
On WRAPSODY, Parra reiterated a $7 million target for the current year. After the CGI period, he said management expects WRAPSODY to be discussed within its platform-level business reporting unless it becomes a material growth driver. He said Merit has additional work underway related to the platform but plans to discuss future products closer to approval, when pricing and other commercial dynamics are clearer.
About Merit Medical Systems (NASDAQ:MMSI)
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Merit Medical Systems NASDAQ: MMSI is preparing its next long-range plan as the medical-device company works through a leadership transition, updates its reporting structure and seeks to build on recent revenue and margin momentum.
Speaking at Bank of America’s virtual SMID Cap event, Chief Financial Officer and Treasurer Raul Parra said Merit operates primarily across interventional radiology, cardiac, endoscopy and breast oncology. He described the company’s differentiators as customer focus, product development, acquisitions, vertical integration, global reach and product quality.
Parra said the company’s organizational changes began more than five years ago under its “Foundations for Growth” initiative, which was designed in part to prepare for founder Fred Lampropoulos’ retirement. With CEO Martha now in place, Merit is placing greater emphasis on accountability across eight business platforms.
Get Merit Medical Systems alerts:
“Now that we have Martha here, we’ve dove into the platforms,” Parra said. “Really that’s how we’re going to start running the business.”
New Reporting Structure and Long-Range Plan Merit recently reorganized its external reporting into Foundational and Therapeutic product categories. Parra said the change was intended to better align external disclosures with how the company operates internally and to help investors understand the procedures, call points and sources of growth across the business.
The Foundational business, which represents about two-thirds of company revenue, includes therapeutic-enabling products such as access, delivery and closure devices. Therapeutics has been growing faster, according to Parra, but the two portfolios remain complementary rather than competing priorities for investment.
Therapeutics posted a three-year compound annual growth rate of about 10%, according to Parra. Foundational products grew at roughly 6% over the same period. Parra said both segments have stronger gross-margin characteristics than investors may expect, with Therapeutics retaining the higher gross margin. The company is conducting a deep review of its operations as it develops its next long-range plan, which Parra said could be announced with the fourth-quarter earnings call or potentially earlier. Management is evaluating whether to present the plan through an earnings call or a separate investor event, potentially in Utah or New York.
Merit has focused its prior plans on revenue growth, operating-margin expansion and free cash flow. Parra said operating margin expanded about 850 basis points from December 2019 through December 2025, and could reach roughly 950 basis points if the company achieves the high end of its current CGI goals by the end of 2026.
While Parra said the company sees further opportunity for margin improvement, he cautioned that management does not expect to repeat the scale of expansion delivered over the past several years.
Second-Quarter Momentum and Margin Drivers Parra said Merit’s second-quarter organic growth was supported by a rebound in its OEM business, resolution of a recall-related issue and continued strength in the underlying business. The company found an alternative product for certain customers affected by the recall, he said.
Merit raised its organic constant-currency revenue outlook, with Parra describing the midpoint as roughly 7% to 7.5% for the year. He said the company was not seeing a slowdown in procedures, although it continues to account for normal third-quarter seasonality and summer vacation patterns.
“The business feels good,” Parra said. “We’re not seeing any slowdown in procedures.”
On profitability, Parra said second-quarter gross-margin expansion reflected product mix, pricing discipline, acquisition performance and operational efficiency. He said acquisitions have generally exceeded expectations on gross margin and have met or surpassed revenue expectations. Merit also has shifted more product transportation from air freight to ocean freight where possible.
Parra said a tariff refund benefited the quarter, though the company used a portion of that benefit to reinvest in initiatives that had been pulled back when tariffs initially affected the business.
M&A Strategy Focused on Existing Platforms Merit intends to continue pursuing acquisitions that deepen its existing positions rather than broadly expanding into new markets, Parra said. Recent deals have supported areas including Oncology, Endoscopy, Cardiac Intervention and Access. He cited the StatSeal acquisition as a Foundational product that can support multiple platforms, while the View Point Medical acquisition added to the Oncology portfolio.
The company sees substantial M&A activity in medical technology, according to Parra, as smaller companies face financing and sales-force-building challenges, European businesses navigate Medical Device Regulation requirements, larger companies seek to streamline operations, and private-equity firms look to sell portfolio companies.
Merit’s acquisition strategy is centered on tuck-in transactions, and Parra said the company would likely seek to keep leverage below three times in the current interest-rate environment. Deal size is less important than whether an asset fills a portfolio need and can be integrated without compromising long-range operating-margin objectives, he said.
Parra said capital allocation, including the relative roles of acquisitions and share repurchases, is part of the company’s strategic-planning process. He also said Merit will evaluate its 2029 convertible debt closer to maturity, potentially considering another convertible issuance or other financing alternatives.
“There’s nobody at Merit thinking that, ‘Hey, we’re done,’” Parra said regarding margin expansion and growth opportunities. “The question right now is how much more.”
About Merit Medical Systems (NASDAQ:MMSI)Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Merit Medical Systems Right Now?Before you consider Merit Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list.
While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Merit Medical Systems NASDAQ: MMSI is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event.
Parra said the company remains “hyper-focused” on executing its current CGI plan and does not want to “drop the football on the one-yard line.” He said the company is working with CEO Martha on the next three-year plan after she spent time visiting company sites and participating in the strategic-planning process.
Get Merit Medical Systems alerts:
While Parra did not provide new targets, he said Merit is evaluating whether the core metrics used in its past long-range plans remain the right measures for the next plan. Those prior targets included organic revenue growth, operating-margin expansion and cumulative free cash flow. The company has previously presented new plans either in November before a program begins or alongside its fourth-quarter results, though Parra said management is also considering whether to provide the update sooner.
Portfolio Review Could Lead to Targeted Changes
Merit is reviewing its portfolio platform by platform to determine where it is performing well, where it needs improvement and which assets may not fit the company’s strategic call points, Parra said. He described the process as “strategic and surgical,” rather than one involving large divestitures.
The company has assembled businesses across oncology, endoscopy, renal therapies and access through acquisitions, Parra said. While he characterized the portfolio as being in attractive markets and procedures, he said there could be opportunities to prune smaller assets that sit outside Merit's primary call points.
Parra cited the company’s divestiture of DualCap as an example of the type of smaller, targeted action management could consider. He said it was too early to determine whether further changes would extend beyond SKU rationalization or involve additional product-line sales.
Margin Efforts Remain Broad-Based
Parra said Merit has delivered 850 basis points of operating-margin improvement and could approach 950 basis points if it reaches the high end of its current-year guidance. He said the company expects further gains to come from continuing to address a broad range of factors, including pricing, sales mix, new product introductions, acquisitions, manufacturing efficiency, automation, lower-cost production transfers, raw materials, scale and logistics.
Rather than relying on a single initiative, Parra said Merit aims to prevent gains in one area from being offset by weaker execution elsewhere. He described the company as being “perpetually” in the seventh inning of margin work: past the heaviest lifting but still able to apply lessons from its prior transformation efforts consistently.
On capital allocation, Parra said Merit remains interested in tuck-in acquisitions across its existing platforms, depending on available opportunities. Share repurchases have also been part of management’s strategic-planning discussions, he said, particularly after medtech stocks experienced pressure earlier in the year.
Management Points to Guidance for Underlying Growth
Merit reported 9% organic growth in the second quarter, its strongest organic-growth result in three years, along with a 22.6% non-GAAP operating margin. Parra said the quarter benefited from an OEM rebound and resolution of a renal recall, but said the result did not surprise management given the underlying performance seen in the first quarter.
The company raised its organic-growth outlook to 6.9% to 7.5% and its adjusted earnings-per-share outlook to $4.25 to $4.35. Parra directed investors to the full-year guidance as the best measure of the company’s expected run rate, while adding that Merit has not seen unusual demand weakness or softness in procedure volumes beyond normal seasonal patterns.
Parra said hospitals could face pressure from broader reimbursement and funding issues, but Merit’s products generally carry a relatively low average selling price and include products such as access, delivery and closure devices that are required in procedures. He said the company’s broad portfolio, vertical integration and product quality help support its value proposition to health systems.
OneMark, Endoscopy and OEM Highlight Growth Areas
Executive Vice President of Corporate Finance and Treasury Travis McDougal said the OneMark acquisition expands Merit's participation earlier in the patient pathway, including lower-risk biopsies, and increases the company’s addressable market to roughly $1.3 billion. He said OneMark and the SCOUT MD platform can serve as part of a continuum of care, although management has incorporated some potential cannibalization into its guidance.
Parra said the company’s sales force is enthusiastic about having a lower-cost option for cases in which the SCOUT system may not be economically appropriate. He added that the OneMark integration is progressing well.
Merit’s endoscopy business grew 29% year over year. Parra said the company does not promise that growth rate will persist, but management is encouraged by the combination of acquired products and new product introductions. McDougal said the segment’s offerings span a patient pathway that includes GERD treatment, Barrett’s esophagus and Merit's legacy endoscopy products.
Parra also said second-quarter OEM performance was broad-based, supported by a new customer agreement and product deliveries. Management expects additional deliveries to that customer in the second half and said it remains confident in mid- to high-single-digit growth for the OEM business.
On WRAPSODY, Parra reiterated a $7 million target for the current year. After the CGI period, he said management expects WRAPSODY to be discussed within its platform-level business reporting unless it becomes a material growth driver. He said Merit has additional work underway related to the platform but plans to discuss future products closer to approval, when pricing and other commercial dynamics are clearer.
About Merit Medical Systems (NASDAQ:MMSI)Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Merit Medical Systems Right Now?Before you consider Merit Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list.
While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
August 05, 2026 12:00 ET | Source: Merit Medical Systems, Inc.
SOUTH JORDAN, Utah, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the upcoming investor conferences:
The Canaccord Genuity 46th Annual Growth Conference, which is being held in Boston, MA from August 11-13, 2026.
Management is scheduled to participate in a fireside chat on Tuesday, August 11th at 11:00 a.m. Eastern Time. The Bank of America SMID Cap Conference, which is being held virtually from August 11-12, 2026.
Management is scheduled to participate in a fireside chat on Wednesday, August 12th at 9:00 a.m. Eastern Time. Live audio webcasts of the fireside chats will be accessible under the “Events” section of the Company’s investor relations website at Investor Events and Presentations - Merit Medical. Replays of the fireside chats will be available on this same website for approximately 90 days.
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide.
Investors interested in Medical - Dental Supplies stocks are likely familiar with The Cooper Companies (COO - Free Report) and Merit Medical (MMSI - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Right now, The Cooper Companies is sporting a Zacks Rank of #2 (Buy), while Merit Medical has a Zacks Rank of #4 (Sell). Investors should feel comfortable knowing that COO likely has seen a stronger improvement to its earnings outlook than MMSI has recently. But this is just one factor that value investors are interested in.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
COO currently has a forward P/E ratio of 16.12, while MMSI has a forward P/E of 20.91. We also note that COO has a PEG ratio of 1.95. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. MMSI currently has a PEG ratio of 2.00.
Another notable valuation metric for COO is its P/B ratio of 1.77. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, MMSI has a P/B of 3.05.
These are just a few of the metrics contributing to COO's Value grade of B and MMSI's Value grade of C.
COO sticks out from MMSI in both our Zacks Rank and Style Scores models, so value investors will likely feel that COO is the better option right now.
Key Takeaways Merit Medical's Q2 adjusted EPS rose 18%, revenues climbed 9.5% and shares gained 4.4% after hours.Therapeutic sales grew 15%, led by 24% growth in Cardiac Therapies and 29% in Endoscopy.Merit Medical raised 2026 revenue guidance to $1.631-$1.643B and adjusted EPS to $4.25-$4.35. Merit Medical Systems, Inc. (MMSI - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of $1.19, up 18% year over year. The figure beat the Zacks Consensus Estimate by 23.9%.
GAAP EPS for the quarter was 65 cents, up 20% year over year.
Shares of MMSI were up 4.4% during after-market trading following the second-quarter results. Year to date, the company’s shares have lost 5.5%, underperforming the industry’s gain of 1.9% and the broader S&P 500 Index’s increase of 8.2%.
Image Source: Zacks Investment Research
MMSI's Q2 Revenue Growth AcceleratesRevenues totaled $418.8 million in the second quarter of 2026, up 9.5% year over year on a reported basis. The metric surpassed the Zacks Consensus Estimate by 3.5%. Total revenues increased 8.7% at constant currency, while organic revenues improved 9% at constant currency.
The U.S. sales amounted to $252.1 million, increasing 11% year over year on a reported basis and 11.5% at constant currency. International revenues totaled $166.8 million, up 7.3% on a reported basis and 4.7% at constant currency.
Merit Medical's Product Mix Stays BalancedFoundational product revenues totaled $280.9 million in the second quarter, up 7% year over year on a reported basis and 6% at constant currency. Excluding contributions from acquired products and the impact of the DualCap divestiture, organic sales increased 7.8%, driven primarily by strength in the Access and Vascular Intervention platforms.
OEM sales increased 15% year over year, reflecting a notable improvement from the first quarter. Procedural Solutions revenues declined 12% due to the DualCap divestiture but increased 5% on an organic basis. Renal Therapies revenues fell 2% at constant currency, while increasing approximately 10% excluding the impact of a product recall.
Therapeutic product revenues amounted to $137.9 million, increasing 15% year over year on a reported basis and 14% at constant currency. Organic sales advanced 11.7%, supported by solid growth across Cardiac Therapies, Endoscopy, Vascular Intervention and Oncology. Cardiac Therapies and Endoscopy revenues rose 24% and 29%, respectively, on a reported basis.
MMSI's Q2 Margin Performance StrengthensIn the quarter under review, Merit Medical’s gross profit increased 16.6% year over year to $215.2 million. The adjusted gross margin expanded 260 basis points (bps) to 55.8%. Excluding tariff refunds recognized during the quarter, the adjusted gross margin was 54.2%, up 98 bps year over year.
Management attributed gross-margin progress to pricing, product mix, acquisition performance, manufacturing transfers, automation and lower reliance on air freight. These gains helped offset tariff pressure while supporting continued investment in the business.
Selling, general and administrative expenses increased 14.3% year over year to $129.2 million. Research and development expenses rose 4.2% to $25.4 million.
Operating profit totaled $60.4 million, reflecting a 28.8% increase from the prior-year quarter. The adjusted operating margin expanded 140 bps to 22.6%. Excluding the tariff refund benefit, the adjusted operating margin was 20.9%, up 22 bps year over year.
Merit Medical's Financial PositionMerit Medical exited second-quarter 2026 with cash and cash equivalents of $448.7 million compared with $488.1 million at the end of the first quarter of 2026. Total long-term debt at the end of the first quarter was $736.3 million compared with $735.2 million in the previous quarter.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $109.9 million compared with $123.9 million a year ago.
Merit Medical Raises 2026 OutlookMMSI has initiated its outlook for third quarter 2026 and raised its outlook for 2026.
For the third quarter of 2026, management expects revenues of $408-$413 million, an adjusted operating margin of 19.6-21.5% and adjusted earnings of $0.98 to $1.08 per share.
For 2026, MMSI raised its revenue guidance to $1.631-$1.643 billion from $1.612-$1.634 billion. The updated range implies reported growth of 7.6-8.4% and constant-currency growth of 6.8-7.6%. Adjusted EPS guidance increased to $4.25-$4.35 from $4.01-$4.15. The Zacks Consensus Estimate for revenues and adjusted EPS is pegged at $1.62 billion and $4.07, respectively.
Wrapping UpMerit Medical continued to advance its oncology platform with the commercial launch of SCOUT MD and preparations for the U.S. rollout of the OneMark Detection Imaging System. Together, the technologies broaden the company’s breast-care offering across diagnosis, localization and surgery. MMSI also progressed with its 2027-2029 strategic planning, focusing on product-pipeline investments, tuck-in acquisitions, portfolio rationalization, productivity and capital allocation.
On the positive side, the integrations of Biolife and the C2 CryoBalloon advanced well, with both businesses contributing above expectations in the second quarter. Merit Medical now expects Biolife to generate approximately $23 million in annualized 2026 revenues, above its initial $18-$20 million view, while C2 CryoBalloon revenues remain projected at approximately $8-$9 million.
However, execution risks remain. The company must successfully integrate View Point Medical and commercialize OneMark while managing tariff uncertainty, acquisition-related risks and potential supply-chain disruptions. Portfolio rationalization and the development of the next three-year growth plan could also require disciplined investment and operating execution.
Merit Medical’s Zacks Rank & Key PicksMerit Medical currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
Merit Medical Systems Inc (NASDAQ:MMSI) posted better-than-expected earnings for the second quarter on Thursday.
The company posted adjusted EPS of $1.19, beating market estimates of 96 cents per share. The company’s sales came in at $418.843 million versus expectations of $405.268 million.
Merit Medical Systems raised its FY2026 adjusted EPS guidance from $4.01-$4.15 to $4.25-$4.35 and increased its sales forecast from $1.612 billion-$1.634 billion to $1.631 billion-$1.643 billion.
Merit Medical shares gained 4.4% to $87.00 in pre-market trading.
These analysts made changes to their price targets on Merit Medical following earnings announcement.
BTIG analyst Sam Eiber maintained the stock with a Buy and raised the price target from $100 to $105. Needham analyst Mike Matson maintained the stock with a Buy and raised the price target from $90 to $101. Considering buying MMSI stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Merit Medical Systems, Inc. (MMSI) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDT
Company Participants
Martha Aronson - President, CEO & Director
Brian Lloyd - Chief Legal Officer & Corporate Secretary
Raul Parra - CFO & Treasurer
Conference Call Participants
Jason Bednar - Piper Sandler & Co., Research Division
Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division
Lei Huang - Wells Fargo Securities, LLC, Research Division
Aidan Lahey - BofA Securities, Research Division
Michael Matson - Needham & Company, LLC, Research Division
Michael Petusky - Barrington Research Associates, Inc., Research Division
Sam Eiber - BTIG, LLC, Research Division
David Rescott - Robert W. Baird & Co. Incorporated, Research Division
Zachary Day - Canaccord Genuity Corp., Research Division
James Sidoti - Sidoti & Company, LLC
Presentation
Operator
Welcome to Merit Medical Systems' Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
I would now like to turn the call over to Martha Aronson, Merit Medical Systems' President and Chief Executive Officer.
Martha Aronson
President, CEO & Director
Thank you, operator, and welcome, everyone. I am joined on the call today by Raul Parra, our Chief Financial Officer and Treasurer; and Brian Lloyd, our Chief Legal Officer and Corporate Secretary.
Brian, would you mind taking us through the safe harbor statements, please?
Brian Lloyd
Chief Legal Officer & Corporate Secretary
Thanks, Martha. This presentation contains forward-looking statements that receive safe harbor protection under federal securities laws. Although we believe these forward-looking statements are based upon reasonable assumptions, they are subject to risks and uncertainties. The realization of any of these risks or uncertainties as well as extraordinary events or transactions impacting our company could cause actual results to differ materially from the expectations and projections expressed or implied by our forward-looking
Merit Medical (MMSI - Free Report) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +23.96%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.84 per share when it actually produced earnings of $0.94, delivering a surprise of +11.9%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Merit Medical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $418.84 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.50%. This compares to year-ago revenues of $382.46 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Merit Medical shares have lost about 8.3% since the beginning of the year versus the S&P 500's gain of 6.9%.
What's Next for Merit Medical?While Merit Medical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Merit Medical was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.03 on $408.67 million in revenues for the coming quarter and $4.07 on $1.62 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Staar Surgical (STAA - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.
This maker of implantable lenses is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of +400%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Staar Surgical's revenues are expected to be $90.77 million, up 104.8% from the year-ago quarter.
Merit Medical (MMSI - Free Report) reported $418.84 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 9.5%. EPS of $1.19 for the same period compares to $1.01 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $404.67 million, representing a surprise of +3.5%. The company delivered an EPS surprise of +23.96%, with the consensus EPS estimate being $0.96.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Merit Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Sales- International: $166.79 million compared to the $165.5 million average estimate based on two analysts. The reported number represents a change of +7.3% year over year.Geographic Sales- United States: $252.05 million compared to the $239.59 million average estimate based on two analysts. The reported number represents a change of +11% year over year.Revenue- Therapeutic: $137.88 million compared to the $132.99 million average estimate based on five analysts.Revenue- Foundational: $280.96 million versus $271.69 million estimated by five analysts on average.View all Key Company Metrics for Merit Medical here>>>
Shares of Merit Medical have returned +16.4% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Financial Highlights† Reported revenue of $418.8 million, up 10% Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively GAAP operating margin of 14.4%, compared to 12.3% in prior year period Non-GAAP operating margin* of 22.6%, compared to 21.2% in prior year period GAAP EPS $0.65, up 20% Non-GAAP EPS* $1.19, up 18% Cash flow from operations of $110.0 million year-to-date, down 11% Free cash flow* generation of $76.6 million year-to-date, down 14% † Comparisons above are calculated for the current quarter compared with the second quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.
Allspring Global Investments Holdings LLC cut its holdings in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) by 75.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,751 shares of the medical instruments supplier’s stock after selling 32,413 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Merit Medical Systems were worth $734,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. State Street Corp lifted its position in shares of Merit Medical Systems by 1.5% during the 4th quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after buying an additional 32,459 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Merit Medical Systems by 3.9% in the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock worth $149,407,000 after acquiring an additional 81,030 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in shares of Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after purchasing an additional 234,682 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Merit Medical Systems by 7.0% during the 4th quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock valued at $116,963,000 after purchasing an additional 86,504 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Merit Medical Systems by 4.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,225,013 shares of the medical instruments supplier’s stock worth $107,974,000 after purchasing an additional 47,151 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.
Insider Activity In other news, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the transaction, the director owned 7,809 shares in the company, valued at approximately $488,921.49. This represents a 39.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brian G. Lloyd bought 2,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The stock was purchased at an average price of $62.62 per share, with a total value of $125,240.00. Following the completion of the purchase, the insider owned 2,000 shares in the company, valued at $125,240. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.70% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth MMSI has been the topic of a number of research analyst reports. Robert W. Baird set a $83.00 target price on shares of Merit Medical Systems in a research report on Friday, May 1st. Canaccord Genuity Group dropped their price target on Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Piper Sandler restated an “overweight” rating on shares of Merit Medical Systems in a research report on Friday, July 10th. Finally, Wall Street Zen cut Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus price target of $92.80.
Read Our Latest Stock Report on Merit Medical Systems
Merit Medical Systems Stock Performance Shares of MMSI stock opened at $76.10 on Tuesday. The stock has a market capitalization of $4.54 billion, a PE ratio of 32.94, a PEG ratio of 2.31 and a beta of 0.52. The business’s 50 day simple moving average is $68.44 and its 200 day simple moving average is $71.89. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. Merit Medical Systems, Inc. has a one year low of $59.74 and a one year high of $94.75.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.10. The firm had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company posted $0.86 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, research analysts forecast that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current year.
Merit Medical Systems Company Profile (Free Report)
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Further Reading Five stocks we like better than Merit Medical Systems AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECetera Investment Advisers Raises Stock Position in Dimensional US Marketwide Value ETF $DFUV
NEXT HEADLINE »Seadrill Limited $SDRL Holdings Boosted by Elliott Investment Management L.P.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI - Free Report) or West Pharmaceutical Services (WST - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Both Merit Medical and West Pharmaceutical Services have a Zacks Rank of #2 (Buy) right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that these stocks have improving earnings outlooks. But this is only part of the picture for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
MMSI currently has a forward P/E ratio of 18.19, while WST has a forward P/E of 41.65. We also note that MMSI has a PEG ratio of 2.05. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. WST currently has a PEG ratio of 2.90.
Another notable valuation metric for MMSI is its P/B ratio of 2.71. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, WST has a P/B of 8.46.
Based on these metrics and many more, MMSI holds a Value grade of B, while WST has a Value grade of D.
Both MMSI and WST are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that MMSI is the superior value option right now.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 17.46; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
Key Takeaways MMSI is positioned for growth with its strong product portfolio, acquisitions and R&D investments.MMSI launched Resilience and acquired View Point, expanding oncology and endoscopy opportunities.MMSI faces tariff costs, China pricing pressure and OEM demand fluctuations in the near term. Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expected to contribute further. However, tariffs and trade policy headwinds, and China macro pressure persist.
This Zacks Rank #2 (Buy) company’s shares have declined 19.4% in the year-to-date period compared with the industry’s 1.2% drop. However, the S&P 500 has risen 9.5% during the same time frame.
The renowned medical device provider has a market capitalization of $4.30 billion. The company projects 8.9% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 12.5% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
MMSI’s Growth DriversStrong Product Portfolio and Strategic Acquisitions: Merit Medical continues to expand its presence across interventional cardiology, radiology, oncology, endoscopy and other minimally invasive procedure markets through a diversified product portfolio and disciplined acquisitions. During the first quarter of 2026, the company launched the Resilience Through-the-Scope Esophageal Stent, which management expects to support long-term growth in its endoscopy business. Merit Medical also acquired View Point Medical, adding the OneMark Detection Imaging System and Tissue Markers to complement its SCOUT platform. Management believes the acquisition expands the addressable procedure opportunity for its oncology business by roughly threefold while providing physicians with additional localization options. Earlier acquisitions, including Biolife and the C2 CryoBalloon technology, continue to strengthen the company's therapeutic portfolio and support long-term growth.
Innovation-Driven R&D: Merit Medical continues to invest in research and development to expand its product pipeline and strengthen its competitive position. The company has reorganized its R&D, marketing and commercial teams around eight product platforms, enabling faster product development and closer alignment with physician needs. Supported by approximately 2,200 patents and patent applications, Merit Medical follows a disciplined innovation strategy that prioritizes products with strong commercial potential and attractive returns, positioning the company for sustained long-term growth.
WRAPSODY Offers Long-Term Upside: Merit Medical's WRAPSODY Cell-Impermeable Endoprosthesis remains an important long-term growth opportunity within renal therapies. Clinical data continue to demonstrate superior long-term vessel patency compared with conventional angioplasty, supporting broader physician adoption. Management reaffirmed its commercial strategy and expects the product to generate approximately $7 million in revenues in the United States in 2026. While adoption remains in the early stages, continued physician education and expanding clinical evidence position WRAPSODY as a meaningful multi-year growth catalyst.
Key Challenges for MMSI StockTariffs and Macroeconomic Uncertainty: Merit Medical continues to operate in an uncertain macroeconomic environment marked by evolving trade policies and geopolitical risks. During the first quarter earnings call, management highlighted tariffs as a significant headwind and expects them to remain a drag on profitability in 2026. While the company has implemented operational initiatives to offset part of the cost pressure, the ultimate impact remains uncertain as it depends on future tariff policies, retaliatory actions and legal developments. Geopolitical disruptions, including those affecting the Middle East, have created temporary shipping delays and higher freight-related costs. Although management described these challenges as manageable, prolonged macroeconomic uncertainty could pressure margins and weigh on earnings growth.
OEM and Pricing Headwinds: Merit Medical continues to face near-term pressure in its OEM business, which has experienced demand fluctuations due to inventory destocking, product line transfers and softer international demand, particularly in the Asia-Pacific region. Management expects these issues to be temporary and continues to view the OEM business as a mid- to high-single-digit grower over the long term. However, broader pricing pressure remains a challenge. The company continues to navigate China's volume-based procurement program, which has reduced pricing in recent years and is expected to remain a headwind in 2026. As Merit Medical expands its therapeutic portfolio through acquisitions and new product launches, sustaining growth will require continued innovation and disciplined execution.
Estimate TrendMMSI is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has remained stable at $4.07.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $404.7 million, suggesting a 5.81% rise from the year-ago reported number. The consensus mark for EPS is pegged at 96 cents, implying a 4.9% decline from the prior-year reported figure.
Other Stocks to ConsiderSome other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Pacific Biosciences of California (PACB - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated earnings growth rate of 5.1% for 2026. VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte’s shares have gained 33.3% against the industry’s 14.2% decline in the year-to-date period.
West Pharmaceutical, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
West Pharmaceutical’s shares have gained 28.5% against the industry’s 1.2% decline in the year-to-date period.
Pacific Biosciences of California, currently carrying a Zacks Rank #2, has an estimated earnings growth rate of 22.6% for 2026. PACB’s earnings beat estimates in each of the trailing four quarters, the average surprise being 29.8%.
Pacific Biosciences’ shares have lost 19.8% compared with the industry’s 14.2% decline in the year-to-date period.
July 02, 2026 16:05 ET | Source: Merit Medical Systems, Inc.
SOUTH JORDAN, Utah, July 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2026, after the close of the stock market on Thursday, July 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, July 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).
To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.
A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com.
ABOUT MERIT
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Merit Medical (MMSI) and West Pharmaceutical Services (WST). But which of these two stocks offers value investors a better bang for their buck right now?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. MMSI has a Momentum Style Score of B, and shares are up 4.8% over the past four weeks.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $4.07 per share. MMSI also boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MMSI should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $4.07 per share. MMSI also boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.54; value investors should take notice.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $4.07 per share. MMSI also boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company conducts its business via two operating segments: Cardiovascular (which includes Peripheral Intervention or PI, Cardiac Intervention or CI, Custom Procedural Solutions or CPS and Original Equipment Manufacturer or OEM and Endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.68; value investors should take notice.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $4.07 per share. MMSI also boasts an average earnings surprise of +13.2%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company conducts its business via two operating segments: Cardiovascular (which includes Peripheral Intervention or PI, Cardiac Intervention or CI, Custom Procedural Solutions or CPS and Original Equipment Manufacturer or OEM and Endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.02 to $4.07 per share. MMSI boasts an average earnings surprise of +13.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
On April 13, 2026, Merit Medical Systems Inc MMSI shares rose 3.4% today, trading at $70.57. The stock has experienced a 52-week range between $66.34 and $100.19, reflecting a volatile trading environment.
GF Value™ verdict: Current price of $70.57 is 26.5% below the GF Value™ estimate of $96.06.GF Score™: 85/100, indicating a strong overall position based on multiple financial metrics.Most notable signal: The momentum rank is low at 2/10, suggesting recent price weakness. Is MMSI Overvalued or Undervalued? Based on the current trading price of $70.57 and the GF Value™ estimate of $96.06, Merit Medical Systems Inc presents a significant margin of safety, standing at 26.5% undervalued. This undervaluation indicates a potential opportunity for investors, as the stock price is well below its intrinsic value according to GuruFocus’ assessment. The GF Valuation label describes MMSI as "Modestly Undervalued," suggesting that while there is an attractive entry point, investors should be cautious of market volatility and the current low momentum rank.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. This method provides a comprehensive view of the company's potential worth, which, in this case, suggests that the stock could recover and align more closely with its estimated fair value over time.
How Does MMSI's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 33.3x 50.1x Forward P/E 17.4x N/A Currently, MMSI's P/E (TTM) of 33.3x is significantly below its 5-year median P/E of 50.1x, indicating that the stock is trading at a lower valuation compared to its historical performance. The forward P/E of 17.4x further emphasizes this disparity, suggesting potential for future earnings growth. This P/E analysis aligns with the GF Value™ verdict that suggests MMSI is undervalued, supporting the notion that there may be room for appreciation if the company meets its growth expectations.
What Does MMSI's GF Score™ Tell Us? Metric Rating GF Score™ 85 Financial Strength 7/10 Profitability 8/10 Growth 9/10 Valuation 8/10 Momentum 2/10 The GF Score™ of 85/100 reflects a strong overall position for Merit Medical Systems Inc, particularly in the categories of Growth (9/10) and Profitability (8/10). These scores suggest that the company has performed well in generating profits and is likely to sustain growth in the future. However, the low Momentum rank of 2/10 indicates recent underperformance, which may deter some investors. Overall, while the fundamentals appear solid, the current momentum weakness should be considered by those evaluating the stock.
What Are Insiders Doing with MMSI Stock? In the last three months, there have been no insider transactions reported for Merit Medical Systems Inc. This lack of trading activity from insiders may indicate a level of confidence in the current valuation and future prospects of the company. However, it may also suggest a lack of immediate catalysts for significant price movement in the short term.
What This Means for Investors Based on the GF Value™ estimate, Merit Medical Systems Inc is currently undervalued. The significant margin of safety suggests potential upside for investors willing to navigate the current market volatility. However, the low momentum rank and lack of insider activity may warrant a cautious approach when considering an investment in MMSI.
For the complete analysis, visit the Merit Medical Systems Inc MMSI stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MMSI's GF Score™?
MMSI has a GF Score™ of 85/100, indicating a strong overall position based on financial metrics and historical performance.
Is MMSI overvalued or undervalued?
According to the GF Value™ estimate, MMSI is undervalued by 26.5%, suggesting significant upside potential based on its intrinsic value.
What is MMSI's P/E ratio?
The current P/E (TTM) ratio for MMSI is 33.3x, which is 34% below its 5-year median P/E of 50.1x, indicating a lower valuation compared to its historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Key Takeaways MMSI growth is driven by strong cardiovascular and peripheral intervention device demand.Therapeutic products outpace foundational offerings, with faster CAGR and rising adoption.Tariffs, China weakness and OEM declines are pressuring margins and near-term growth. Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expected to contribute further. However, tariffs and trade policy headwinds, and China macro pressure persist.
This Zacks Rank #3 (Hold) company’s shares have declined 20% in the year-to-date period compared with the industry’s 1.8% drop. However, the S&P 500 has risen 0.5% during the same time frame.
The renowned medical device provider has a market capitalization of $4.21 billion. The company projects 9.5% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 13.2% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
MMSI’s Growth DriversStrength in Cardiovascular & Peripheral Intervention Devices: The cardiovascular segment remains the main growth engine for Merit Medical, showing strong results driven by cardiac and peripheral intervention products. Cardiac intervention sales remain supported by demand for electrophysiology, cardiac rhythm management, angiography and vascular access offerings.
Peripheral intervention product growth is driven by strong sales in radar localization and delivery systems, reflecting wider adoption across embolotherapy, drainage, angiography and access categories. This momentum is expected to persist into 2026.
Expansion of Therapeutic Products & Innovation: Merit Medical’s therapeutic portfolio is outpacing its foundational products, emerging as a growth driver. Foundational products delivered a 6% CAGR over the past three years. In comparison, therapeutic products have grown with a 19% CAGR over the same period. This segment has become a major growth driver, reflecting rising physician adoption of devices that focus on treatment rather than procedural support.
Product Innovation & Acquisitions: Growth in 2025 was supported by a mix of internal product development and acquisitions. Product launches such as the Resilience Through-the-Scope Esophageal Stent, Prelude SNAP system, Ventrax Delivery System, Prelude radial sheath and SCOUT radar localization system gained traction. The recent acquisition of View Point Medical is projected to generate between $2 million and $4 million in revenues in 2026.
Key Challenges for MMSI StockTariffs & Trade Policy Pressuring Margins: Tariffs weighed on gross margin performance in fourth-quarter 2025, with a 112-basis-point year-over-year impact. Management expects this pressure to continue into 2026. Guidance for the year includes a projected tariff impact of $15 million, or 19 cents per share, compared with $9 million, or 12 cents per share, recorded during the last eight months of 2025.
In the near term, tariffs are expected to create an 80-basis-point, or $3 million, gross margin impact in first-quarter 2026, which adds uncertainty around future cost pressure and margin performance.
OEM Weakness & China Macro Pressure: The company saw weakness in its OEM business in the United States due to softer performance driven by customer inventory destocking, which reduced order volumes from OEM partners. Outside the United States, demand faced pressure in China due to the impact of the country’s volume-based procurement program, which has pressured pricing across medical device categories.
Despite near-term volatility, the company expects the OEM segment to return to a mid- to high-single-digit growth range over time, though near-term fluctuations may persist.
Estimate TrendMMSI is witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved 0.5% north to $4.07.
The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pegged at $377.5 million, suggesting a 6.23% rise from the year-ago reported number. The consensus mark for EPS is pegged at 84 cents, implying a 2.3% decline from the prior-year reported figure.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Cardinal Health (CAH - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated earnings recession rate of 1.9%. PACB’s earnings surpassed estimates in the trailing four quarters, the average surprise being 27.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pacific Biosciences’ shares have lost 16% compared with the industry’s 12.9% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 15%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.3%.
Cardinal Health’s shares have gained 4.6% against the industry’s 1.9% decline in the year-to-date period.
GE HealthCare Technologies, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 9.1%. GEHC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 7.5%.
GE HealthCare Technologies’ shares have lost 9% compared with the industry’s 13.4% decline in the year-to-date period.
Financial Highlights† Reported revenue of $381.9 million, up 7% Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year period Non-GAAP operating margin* of 19.7%, compared to 19.3% in prior year period GAAP EPS $0.68, up 39% Non-GAAP EPS* $0.94, up 9% Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25.5 million was paid in cash at closing On April 1, 2026, Merit acquired View Point Medical, Inc., manufacturer of the OneMark® Detection Imaging System and OneMark Tissue Markers, for $140 million, of which $90 million was paid in cash at closing Beginning in the first quarter of 2026, Merit reorganized the presentation of revenue into two product categories – Foundational and Therapeutic - to better reflect the clinical uses of our diverse portfolio of products** † Comparisons above are calculated for the current quarter compared with the first quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.
Merit Medical (MMSI - Free Report) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.86 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +12.13%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.96 per share when it actually produced earnings of $1.04, delivering a surprise of +8.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Merit Medical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $381.88 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.28%. This compares to year-ago revenues of $355.35 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Merit Medical shares have lost about 26.4% since the beginning of the year versus the S&P 500's gain of 4.2%.
What's Next for Merit Medical?While Merit Medical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Merit Medical was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $411.1 million in revenues for the coming quarter and $4.04 on $1.61 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Dentsply International (XRAY - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 5.
This dental products manufacturer is expected to post quarterly earnings of $0.28 per share in its upcoming report, which represents a year-over-year change of -34.9%. The consensus EPS estimate for the quarter has been revised 3.9% lower over the last 30 days to the current level.
Dentsply International's revenues are expected to be $840.06 million, down 4.4% from the year-ago quarter.
Key Takeaways MMSI posted Q1 EPS of 94 cents, beating estimates by 11.9% and rising 9% year over year.Revenues reached $381.9M, up 7%, driven by growth in both Foundational and Therapeutic segments.MMSI raised 2026 revenue outlook to $1.612-$1.634B while maintaining EPS guidance of $4.01-$4.15. Merit Medical Systems, Inc. (MMSI - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of 94 cents, up 9% from the year-ago quarter’s level. The bottom line surpassed the Zacks Consensus Estimate by 11.9%.
GAAP EPS for the quarter was 63 cents, up 39% year over year.
MMSI’s Revenue DetailsRevenues amounted to $381.9 million in the reported quarter, up 7% year over year on a reported basis. The metric topped the Zacks Consensus Estimate by 1.3%.
Total revenues at constant exchange rate (CER) increased 5.2% year over year, whereas CER organic revenues improved 3.7%.
Merit Medical’s Geographic ResultsThe U.S. sales amounted to $226.5 million, which increased 6.1% year over year on a reported basis and 6.8% at CER. Our first-quarter projection was $228 million for the metric.
International sales amounted to $155.4 million, up 9.6% year over year on a reported basis and 2.9% at CER. This figure compares to our projection of $148.7 million.
MMSI’s Segmental DetailsBeginning first-quarter 2026, Merit Medical started operating through two product categories — Foundational (67% of sales) and Therapeutic (33% of sales). Foundational products are used primarily for access and enabling functions in vascular and other procedures. Therapeutic products include devices and systems. The company previously reported under two categories — Cardiovascular and Endoscopy.
The Foundational category reported first-quarter revenues of $255.5 million, up 6% on a reported basis and 4% at CER year over year.
Therapeutic unit’s revenues totaled $126.4 million, up 10% year over year on a reported basis and 5% at CER.
Merit Medical’s Margin AnalysisIn the quarter under review, Merit Medical’sgross profit increased 7.4% year over year to $184.8 million. The adjusted gross margin contracted 20 basis points (bps) to 53.2%. We had projected a 53.3% gross margin for the first quarter.
Selling, general & administrative expenses increased 10% year over year to $118.2 million. Research and development expenses rose 0.6% year over year to $22.6 million.
Operating profit totaled $44.2 million, reflecting a 7.6% increase from the prior-year quarter’s level. The adjusted operating margin in the first quarter expanded 40 bps to 19.7%.
MMSI’s Financial PositionMerit Medical exited first-quarter 2026 with cash and cash equivalents of $488.1million compared with $446.4 million at the end of the fourth quarter of 2025. Total long-term debt at the end of the first quarter was $735.2 million compared with $734 million in the previous quarter.
Cumulative net cash provided by operating activities at the end of first-quarter 2026 was $40.7 million compared with $40.6 million a year ago.
Merit Medical’s GuidanceMMSI has updated its outlook for2026.
Net revenues for 2026 are projected to be between $1.612billion and $1.634 billion (reflecting an increase of 6-8% year over year on a reported basis), up from the previous guidance of $1.610-$1.630 billion. The Zacks Consensus Estimate is pegged at $1.61 billion.
The company has maintained its guidance for 2026 adjusted EPS of $4.01-$4.15 (implying an increase of 5-8% year over year). The Zacks Consensus Estimate is pegged at $4.04.
Our Take on MMSIMerit Medical exited the first quarter of 2026 with better-than-expected results. The year-over-year uptick in the top and bottom lines was impressive. The company’s organic growth remained modest at 2.7% (3.7% ex-divestiture), but was supplemented by acquisitions. Profitability stood out as operating margin expanded to a record 19.7% and EPS grew 9%, both ahead of guidance. Free cash flow increased 26%, reflecting disciplined cost control and improving operational execution.
Looking ahead, growth should be supported by expansion in higher-growth therapeutic segments, new product launches such as the Resilience stent, and the View Point Medical acquisition, which strengthens the oncology platform and expands addressable markets. However, challenges persist, including OEM revenue volatility, tariff-related margin pressure, and macro headwinds in APAC. The DualCap divestiture and near-term acquisition may weigh on growth and earnings cadence. Despite these factors, management maintains confidence in steady growth and margin improvement through 2026.
Merit Medical’s shares have lost 22.6% so far this year compared with the industry’s decline of 6%. The S&P 500 Index has risen 4.5% in the same period.
Image Source: Zacks Investment Research
Merit Medical’s Zacks Rank and Key PicksMerit Medical currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy) at present, Phibro Animal Health and Cardinal Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical’s shares have gained 3.3% in the year-to-date period. Estimates for the company’s first-quarter 2026 EPS have increased 1 cent to 90 cents in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 18.79%. In the last reported quarter, it posted an earnings surprise of 20.75%.
Estimates for Phibro Animal Health’s third-quarter fiscal 2026 EPS have remained constant at 72 cents in the past 30 days. Shares of the company have risen 42.4% in the year-to-date period against the industry’s 20.5% decline. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.15%. In the last reported quarter, it delivered an earnings surprise of 26.09%.
Cardinal Health’s shares have declined 6.2% in the year-to-date period. Estimates for the company’s third-quarter 2026 EPS have decreased 1 cent to $2.80 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.30%. In the last reported quarter, it posted an earnings surprise of 10.04%.
Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company conducts its business via two operating segments: Cardiovascular (which includes Peripheral Intervention or PI, Cardiac Intervention or CI, Custom Procedural Solutions or CPS and Original Equipment Manufacturer or OEM and Endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.33; value investors should take notice.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.00 to $4.05 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
May 08, 2026 09:25 ET | Source: Merit Medical Systems, Inc.
SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit management will participate in the Bank of America 2026 Health Care Conference, to be held in Las Vegas, Nevada, May 12-14, 2026.
The management team will participate in a fireside chat session on Tuesday, May 12th at 3:00 pm Pacific Time / 6:00 pm Eastern Time.
A live audio webcast of the fireside chat will be accessible under the “Events” section of the Company’s investor relations website at Investor Events and Presentations - Merit Medical. A replay of the fireside chat will be available on this same website for approximately 90 days.
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.
Lynne N. Ward, Director at Merit Medical Systems (MMSI 0.76%), reported an open-market sale of 5,000 shares for a total of approximately $313,000, according to the SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)5,000Transaction value~$313,000Post-transaction shares (direct)7,809Post-transaction value (direct ownership)~$489,000Transaction and post-transaction value based on SEC Form 4 weighted average purchase price ($62.61).
Key questionsHow did the transaction affect Lynne Ward's ownership in Merit Medical Systems?
The sale reduced Ward's direct holdings by 39%, from 12,809 shares to 7,809 shares, with no remaining indirect or derivative securities reported.Were any other forms of disposition, such as gifts or withholdings, involved in this filing?
No; the filing strictly reflects a direct open-market sale, with no gifts or shares withheld for taxes or administrative purposes.What does the transaction size indicate about Ward's trading pattern and remaining capacity?
The 5,000-share sale is the only open-market sale in the last twelve months and reflects a larger proportion of Ward's shrinking available holdings, consistent with the ongoing reduction in position size.What continuing interest does Ward have in Merit Medical Systems following this sale?
Despite the reduction, Ward retains 7,809 shares of Common Stock (direct), maintaining a continuing ownership position.Company overviewMetricValueRevenue (TTM)$1.54 billionNet income (TTM)$139.34 millionEmployees7,4001-year price change(36.06%)* 1-year price change calculated using May 7, 2026 as the reference date.
Company snapshotMerit Medical Systems designs, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, with a focus on cardiology, radiology, oncology, critical care, and endoscopy.It generates revenue through the direct sale and distribution of proprietary medical devices and custom procedural solutions to healthcare providers and OEM partners.The company serves hospitals, physicians, technicians, and nurses in the United States and international markets through a combination of direct sales and distributor relationships.Merit Medical Systems, Inc. is a leading provider of single-use medical devices, operating at scale with over 7,400 employees and a global footprint. The company's strategy centers on innovation in minimally invasive procedures and procedural efficiency, supporting its competitive position in the medical instruments and supplies sector.
Merit Medical's diversified product portfolio and broad customer base drive consistent demand across major healthcare markets.
What this transaction means for investorsThe May 7 sale of Merit Medical stock by Board of Directors member Lynne Ward comes at a time when shares were on the decline. The stock eventually hit a 52-week low of $59.74 on May 12, not long after War’s disposition, and far from an ideal time to sell.
The price drop was due to Wall Street’s concerns over macroeconomic headwinds. Higher tariffs, in particular, can hurt Merit Medical’s business performance.
Another investor concern is decelerating growth. Merit’s 2026 guidance of about $1.6 billion in sales was not a large step up from the prior year’s $1.5 billion, when the company experienced a 12% year-over-year increase.
Over the long term, Merit Medical shares can recover, once macroeconomic headwinds pass. That may be one reason why Lynne Ward held on to 7,809 shares after her sale, suggesting the May 7 disposition may have been for personal reasons, and not a lack of faith in the company’s long-term success.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
May 19, 2026 09:15 ET | Source: Merit Medical Systems, Inc.
SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders elected Scott R. Ward to the company’s Board of Directors at Merit’s annual meeting of shareholders.
Mr. Ward was elected to serve a three-year term.
“On behalf of the Board, we are pleased with Scott Ward’s election to Merit’s Board of Directors,” said F. Ann Millner, Merit’s Chair of the Board. “Scott’s extensive industry experience, strategic insight, and commitment to innovation will be tremendous assets as we continue advancing the company’s strategic priorities.”
“We are proud to welcome Scott Ward to Merit’s Board,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “Scott brings deep medical device experience and a proven leadership track record. As we continue building on our foundation and advancing our strategy, his perspective will be invaluable to our long-term growth.”
“I am honored to join the Merit Board of Directors,” Ward said. “I have great respect for Merit’s commitment to innovation and its focus on serving patients and healthcare providers around the world. I look forward to contributing my experience as the company continues to grow and expand its impact.”
Mr. Ward brings more than 40 years of experience in the healthcare and medical device industry, including nearly three decades at Medtronic, where he held senior leadership roles such as senior vice president and president of the cardiovascular, neurological, and diabetes businesses. He most recently served as CEO, President and Chairman of Cardiovascular Systems, Inc., leading the company through a period of expansion and its acquisition by Abbott.
Mr. Ward is also the founder of Raymond Holdings, a firm focused on venture capital, strategy, and advisory services for medical technology and life sciences companies, and has served on numerous public and private company boards. Merit’s Board of Directors has appointed Mr. Ward to serve on its Governance and Sustainability and Finance and Operating Committees.
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MMSI has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.3% for the current fiscal year.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.00 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MMSI should be on investors' short list.
On May 27, 2026, Merit Medical Systems Inc MMSI shares fell 3.1% to a current price of $62.52. This decline is part of a broader trend, with the stock down 29.1% year-to-date and 35.2% over the past year, while trading within a 52-week range of $59.74 to $97.18.
GF Value™ verdict: The current price is $62.52, which is 35.0% below the GF Value™ estimate of $96.19.GF Score™: At 79/100, the stock is rated as Above Average, indicating potential for long-term returns.Most notable signal: Insider activity shows that insiders bought $0.6M and sold $0.3M in the last 3 months, indicating some level of confidence in the company’s prospects. Is MMSI Overvalued or Undervalued? The GF Value™ of Merit Medical Systems Inc MMSI is estimated at $96.19, suggesting that the stock is currently undervalued at a price of $62.52. This presents a margin of safety of 35.0%, indicating a significant upside potential. The GF Valuation label classifies the stock as significantly undervalued, which implies that the market may not be fully recognizing the company’s growth prospects and financial health. However, while the undervaluation presents an opportunity, investors should remain cautious, as fluctuations in market sentiment or company performance could impact this valuation.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Therefore, the current price level could be viewed as an attractive entry point for long-term investors, provided that the company's fundamentals remain strong and the broader market conditions are favorable.
How Does MMSI's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 27.1x 49.1x Forward P/E 15.4x N/A The current P/E (TTM) of 27.1x is significantly below its 5-year median P/E of 49.1x, indicating that MMSI is trading at a discount compared to its historical valuation. Additionally, the forward P/E of 15.4x suggests further potential for growth. This P/E analysis aligns with the GF Value™ verdict of undervaluation, reinforcing the notion that the stock may be undervalued relative to its historical performance.
What Does MMSI's GF Score™ Tell Us? Metric Rating GF Score™ 79 Financial Strength 7/10 Profitability 8/10 Growth 9/10 Valuation 4/10 Momentum 2/10 The GF Score™ of 79 indicates that Merit Medical Systems Inc MMSI has solid fundamentals, particularly in Growth (9/10) and Profitability (8/10), suggesting the company has the potential to generate strong returns. However, the Valuation score of 4/10 and a Momentum rank of 2/10 highlight areas of concern, indicating that while the underlying business may be strong, the stock may lack the momentum needed to attract new investors in the short term.
What Are Insiders Doing with MMSI Stock? In the past three months, there has been notable insider activity at Merit Medical Systems Inc MMSI , with insiders purchasing $0.6 million worth of shares while also selling $0.3 million. This pattern of buying amidst some selling may suggest that insiders are optimistic about the company's future performance, as they are willing to increase their stake even while realizing some profits. Such insider buying can be viewed as a positive signal about the company’s prospects.
What This Means for Investors Based on the GF Value™ assessment, Merit Medical Systems Inc MMSI is currently undervalued. At a current price of $62.52 compared to an estimated GF Value™ of $96.19, there is a substantial margin for potential upside. However, investors should also consider the factors impacting the stock's momentum and the broader market environment.
For the complete analysis, visit the Merit Medical Systems Inc MMSI stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MMSI's GF Score™?
MMSI has a GF Score™ of 79/100, indicating that it has strong potential for long-term returns based on its financial health and growth prospects.
Is MMSI overvalued or undervalued?
According to GF Value™, MMSI is undervalued, with a current price of $62.52 being 35.0% below the estimated fair value of $96.19.
What is MMSI's P/E ratio?
The current P/E (TTM) for MMSI is 27.1x, which is significantly lower than its 5-year median P/E of 49.1x, suggesting it is trading at a discount compared to its historical average.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Merit Medical (MMSI - Free Report) South Jordan, UT-headquartered Merit Medical Systems, Inc. designs, manufactures and markets proprietary medical devices used in interventional, diagnostic and therapeutic procedures. The company serves a wide range of clinical areas, including cardiology, radiology, oncology, critical care and endoscopy.
MMSI is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.26; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.00 to $4.07 per share. MMSI boasts an average earnings surprise of +12.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, MMSI should be on investors' short list.
